Cordis

Stuart Therapeutics Announces Chief Medical and Chief Financial Officer Appointments

Retrieved on: 
Thursday, February 1, 2024

STUART, Fla., Feb. 1, 2024 /PRNewswire/ -- Stuart Therapeutics, Inc. ("Stuart"), a clinical-stage biopharmaceutical company with candidate therapeutics in various phases of clinical development, today announced that it has appointed Jodi Luchs, MD to the position of Chief Medical Officer, and Don Stires to the position of Chief Financial Officer.

Key Points: 
  • STUART, Fla., Feb. 1, 2024 /PRNewswire/ -- Stuart Therapeutics, Inc. ("Stuart"), a clinical-stage biopharmaceutical company with candidate therapeutics in various phases of clinical development, today announced that it has appointed Jodi Luchs, MD to the position of Chief Medical Officer, and Don Stires to the position of Chief Financial Officer.
  • With the appointment of Dr. Luchs, Robert Baratta, MD has stepped aside from his current role as Chief Medical Officer but will continue as Stuart's Executive Chairman of the Board.
  • "Stuart Therapeutics' growth, international operations and increase in pipeline opportunities require an expansion of our team and capabilities," said Eric Schlumpf, President and Chief Executive Officer of Stuart.
  • He completed an internship at the Mount Sinai Medical Center, and his Ophthalmology residency at Long Island Jewish Medical Center.

Ajax Health Establishes Cortex, a Comprehensive AFib Ablation Technology Company, with $90 Million Investment Led by KKR and Hellman & Friedman

Retrieved on: 
Thursday, December 7, 2023

MENLO PARK, Calif., Dec. 7, 2023 /PRNewswire/ -- Ajax Health announced today the formation and funding of Cortex, a medical technology company developing an integrated mapping and ablation solution suite for the treatment of atrial fibrillation (AFib), the most common heart rhythm disorder, affecting more than 30 million patients worldwide. Cortex has raised $90 million in funding commitments led by KKR and Hellman & Friedman (H&F) with participation by other investors including AI Life Sciences, an affiliate of Access Industries.

Key Points: 
  • Cortex has raised $90 million in funding commitments led by KKR and Hellman & Friedman (H&F) with participation by other investors including AI Life Sciences, an affiliate of Access Industries.
  • Cortex brings together expert teams with complementary innovations in electrophysiology to accelerate the continued development and clinical validation of next-generation ablation solutions and differentiated AFib mapping technology.
  • "Cortex's vision is to enable more intelligent AFib treatment," said Duke Rohlen, CEO of Ajax Health and CEO of Cortex.
  • EGF mapping allows physicians to detect AFib sources and is designed to support personalized ablation therapy to potentially improve outcomes.

Lecheng, MSD vow to deepen medical cooperation

Retrieved on: 
Friday, November 10, 2023

The Lecheng delegation visited the booths of "new friends" such as Grifols, Chiesi, FANCL, and Cordis, and engaged in discussions and exchanges to establish a solid foundation for future cooperation.

Key Points: 
  • The Lecheng delegation visited the booths of "new friends" such as Grifols, Chiesi, FANCL, and Cordis, and engaged in discussions and exchanges to establish a solid foundation for future cooperation.
  • They also deepened their cooperation with "old friends" like Novartis, MSD, Sanofi, AbbVie, Bayer, Roche, Lilly, Johnson & Johnson, Amgen, Carl Zeiss, Gilead, Pfizer, Boston Scientific, Roche Diagnostics, Intuitive Surgical, and Allergan.
  • It was at this year's expo that MSD launched its MSD (Hainan) Innovative Medical Co Ltd, on November 6.
  • MSD, headquartered in New Jersey, the United States, is a leading global pharmaceutical company with a focus on research, development and the sale of innovative medical products.

HeartBeam Announces Expansion of Its Scientific Advisory Board

Retrieved on: 
Thursday, November 9, 2023

HeartBeam, Inc. (NASDAQ: BEAT), a cardiac technology company that has developed the first and only credit card-size 3D-vector electrocardiogram (VECG) platform for patient use at home, allowing for the creation of rich data for AI, today announced the expansion of its Scientific Advisory Board (SAB) to include several leading cardiologists.

Key Points: 
  • HeartBeam, Inc. (NASDAQ: BEAT), a cardiac technology company that has developed the first and only credit card-size 3D-vector electrocardiogram (VECG) platform for patient use at home, allowing for the creation of rich data for AI, today announced the expansion of its Scientific Advisory Board (SAB) to include several leading cardiologists.
  • He is a world-renowned expert in interventional cardiology, and an accomplished inventor, entrepreneur, and investment fund founder.
  • “We are honored and pleased to have such a distinguished group of physicians joining our Scientific Advisory Board,” said Branislav Vajdic, Ph.D., CEO and Founder of HeartBeam.
  • “HeartBeam will benefit tremendously from the input of these leaders in interventional cardiology, electrophysiology, clinical research, and new technologies.

Cordis Announces Scott Drake as Chief Executive Officer

Retrieved on: 
Monday, November 6, 2023

MIAMI LAKES, Fla., Nov. 6, 2023 /PRNewswire/ -- Cordis announced that its Board of Directors has appointed Scott Drake as Chief Executive Officer (CEO) effective immediately.

Key Points: 
  • MIAMI LAKES, Fla., Nov. 6, 2023 /PRNewswire/ -- Cordis announced that its Board of Directors has appointed Scott Drake as Chief Executive Officer (CEO) effective immediately.
  • Mr. Drake most recently held the position of Executive Chairman of the Cordis Board of Directors.
  • "Scott Drake has been on the Cordis Board of Directors since we acquired Cordis in 2021," said Hunter Philbrick, H&F partner and Cordis board member.
  • Scott believes in Cordis' ability to transform the medical industry, and with him as CEO, Cordis will achieve its vision of pioneering breakthrough cardiovascular technologies."

Global Vascular Closure Devices Market Projected to Reach $1.4 Billion by 2030, Driven by Cardiovascular Health Focus - ResearchAndMarkets.com

Retrieved on: 
Monday, October 9, 2023

The "Vascular Closure Devices - Global Strategic Business Report" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Vascular Closure Devices - Global Strategic Business Report" report has been added to ResearchAndMarkets.com's offering.
  • The global market for Vascular Closure Devices, estimated at US$824.6 million in 2022, is poised for substantial growth, projected to reach a revised size of US$1.4 billion by 2030, with a notable CAGR of 7.3% over the analysis period from 2022 to 2030.
  • Meanwhile, the growth in the Active Approximators segment is estimated at a commendable 6.5% CAGR for the next 8-year period.
  • The U.S. Market is Estimated at $340.6 Million, While China Shows Strong Growth
    In the United States, the Vascular Closure Devices market is estimated at US$340.6 million in 2022.

JenaValve Appoints Shlomi Nachman to Board of Directors

Retrieved on: 
Thursday, September 14, 2023

IRVINE, Calif., Sept. 14, 2023 (GLOBE NEWSWIRE) -- JenaValve Technology, Inc., developer and manufacturer of differentiated transcatheter aortic valve replacement (TAVR) systems, today announced that it has appointed Shlomi Nachman, experienced cardiovascular industry executive, to its Board of Directors.

Key Points: 
  • IRVINE, Calif., Sept. 14, 2023 (GLOBE NEWSWIRE) -- JenaValve Technology, Inc., developer and manufacturer of differentiated transcatheter aortic valve replacement (TAVR) systems, today announced that it has appointed Shlomi Nachman, experienced cardiovascular industry executive, to its Board of Directors.
  • “We are thrilled to welcome Shlomi to the JenaValve Board of Directors,” said John Kilcoyne, Chief Executive Officer.
  • “His experience as both an executive and board member across innovative cardiovascular device businesses further strengthens the operating expertise of our board.
  • Mr. Nachman stated, “I am grateful to have the opportunity to join JenaValve at such an exciting time in the company’s development.

Cordis Names Scott Drake Executive Chairman

Retrieved on: 
Tuesday, September 5, 2023

MIAMI LAKES, Fla., Sept. 5, 2023 /PRNewswire/ -- Cordis , a worldwide leader in the development and manufacturing of interventional cardiovascular and endovascular technology, today announced the appointment of Scott Drake as Executive Chairman of its Board of Directors.

Key Points: 
  • MIAMI LAKES, Fla., Sept. 5, 2023 /PRNewswire/ -- Cordis , a worldwide leader in the development and manufacturing of interventional cardiovascular and endovascular technology, today announced the appointment of Scott Drake as Executive Chairman of its Board of Directors.
  • Drake, who joined the Cordis board in August of 2021, succeeds Duke Rohlen who served as Executive Chairman since the acquisition of Cordis, also in 2021, by Hellman & Friedman and KKR.
  • Scott Drake has over 30 years of medical device experience.
  • Mr. Drake will provide experienced leadership to effectively integrate the potential of the Cordis-X accelerator into the world class operational company of Cordis.

Amarin Appoints Patrick Holt as President and Chief Executive Officer

Retrieved on: 
Tuesday, July 18, 2023

DUBLIN, Ireland and BRIDGEWATER, N.J., July 18, 2023 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ: AMRN) today announced that the Company’s Board of Directors has appointed Patrick Holt as President and Chief Executive Officer and as a member of the Board of Directors, effective immediately.

Key Points: 
  • DUBLIN, Ireland and BRIDGEWATER, N.J., July 18, 2023 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ: AMRN) today announced that the Company’s Board of Directors has appointed Patrick Holt as President and Chief Executive Officer and as a member of the Board of Directors, effective immediately.
  • Aaron Berg, who served as Interim President and CEO since April 2023, will remain with the Company in a senior leadership role.
  • Mr. Holt brings more than 25 years of leadership in the life sciences industry and significant international operating experience.
  • Mr. Holt previously held a variety of senior executive positions across biopharmaceuticals and vaccines at Allergan and Merck.

Florida Food Products Names Kevin Neat Chief Financial Officer

Retrieved on: 
Friday, May 5, 2023

Florida Food Products, LLC (“FFP” or the “Company”), one of the world’s largest independent providers of natural ingredients, today announced that Kevin Neat, former Chief Financial Officer of Johnson & Johnson’s (“J&J”) North American Consumer Health business (now publicly listed as Kenvue), has joined the Company as Chief Financial Officer.

Key Points: 
  • Florida Food Products, LLC (“FFP” or the “Company”), one of the world’s largest independent providers of natural ingredients, today announced that Kevin Neat, former Chief Financial Officer of Johnson & Johnson’s (“J&J”) North American Consumer Health business (now publicly listed as Kenvue), has joined the Company as Chief Financial Officer.
  • Mr. Neat will be a part of FFP's executive leadership team and is responsible for overseeing all aspects of FFP’s financial and IT functions.
  • Mr. Neat boasts more than two decades of international experience leading high performance finance teams at companies across the consumer packaged goods, healthcare, aerospace, and chemical manufacturing industries.
  • Most recently, as Chief Financial Officer of J&J’s $8 billion North American Consumer Health business, Mr. Neat oversaw the business responsible for some of the world’s best-known brands, including Band-Aid, Tylenol, and Neutrogena, among others.